Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.

Keywords

Internal medicineLipogenesisNonalcoholic fatty liver diseaseEndocrinologyFatty liverHypertriglyceridemiaVery low-density lipoproteinLipoproteinBiologyAdipose tissueChylomicronLiver biopsyCholesterolMedicineTriglycerideBiopsyDisease

Affiliated Institutions

Related Publications

Publication Info

Year
2005
Type
article
Volume
115
Issue
5
Pages
1343-1351
Citations
3351
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

3351
OpenAlex

Cite This

Kerry L. Donnelly, Coleman I. Smith, Sarah Jane Schwarzenberg et al. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation , 115 (5) , 1343-1351. https://doi.org/10.1172/jci23621

Identifiers

DOI
10.1172/jci23621